ERBB2 and cancer: Among antibodies, two clinically approved monoclonal antibodies, cetuximab (anti-EGFR) and trastuzumab (anti-HER-2) were used to functionalize AuNPs for enhanced cancer radiotherapy or to depict and quantify high and low tumoral surface marker expression [114,115].